"hivウイルス" の関連情報検索結果
Women and HIV: Get the Facts on HIV Testing, Prevention, and Treatment - fda.gov

Women and HIV: Get the Facts on HIV Testing, Prevention, and Treatment fda.gov
London patient remains HIV-free after 2.5 years off treatment - Aidsmap

London patient remains HIV-free after 2.5 years off treatment Aidsmap
A Hidden Defense Inside Llamas Could Be The Secret to Fighting HIV - ScienceAlert

A Hidden Defense Inside Llamas Could Be The Secret to Fighting HIV ScienceAlert
Test and treat studies show high rates of HIV diagnosis, viral suppression - Aidsmap

Test and treat studies show high rates of HIV diagnosis, viral suppression Aidsmap
Some children who start antiretrovirals very early may control HIV after stopping treatment - Aid...

Some children who start antiretrovirals very early may control HIV after stopping treatment Aidsmap
After viral rebound, dolutegravir-based treatment more likely to suppress HIV - Aidsmap

After viral rebound, dolutegravir-based treatment more likely to suppress HIV Aidsmap
São Paulo patient experiences apparent viral rebound a year and a half after stopping HIV treatme...

São Paulo patient experiences apparent viral rebound a year and a half after stopping HIV treatment Aidsmap
Lenacapavir shows continued promise for first-line treatment and highly resistant HIV - Aidsmap

Lenacapavir shows continued promise for first-line treatment and highly resistant HIV Aidsmap
Therapeutic vaccine shows potential for HIV control off treatment in early study - Aidsmap

Therapeutic vaccine shows potential for HIV control off treatment in early study Aidsmap
Sharing anti-HIV medication is common in rural Uganda - Aidsmap

Sharing anti-HIV medication is common in rural Uganda Aidsmap
New cases of multi-drug resistant HIV becoming rarer in Europe - Aidsmap

New cases of multi-drug resistant HIV becoming rarer in Europe Aidsmap
One person remains undetectable without HIV drugs almost four years after using an antibody-based...

Child with HIV maintains viral suppression for three years off treatment - Aidsmap

Child with HIV maintains viral suppression for three years off treatment Aidsmap
Nearly a third of babies with HIV given ART very soon after birth have no HIV antibodies two year...

People with HIV gain weight faster than HIV-negative people - Aidsmap

People with HIV gain weight faster than HIV-negative people Aidsmap
Broadly neutralising antibody treatment: is pre-existing resistance its Achilles heel? - Aidsmap

Broadly neutralising antibody treatment: is pre-existing resistance its Achilles heel? Aidsmap
Lung function declines faster in people living with HIV - Aidsmap

Lung function declines faster in people living with HIV Aidsmap
‘Molecular scissors’ successfully remove HIV genes from all tissues in infected monkeys - Aidsmap

‘Molecular scissors’ successfully remove HIV genes from all tissues in infected monkeys Aidsmap
Reappearance of HIV in "Mississippi Baby" poses questions for early treatment - Aidsmap

Reappearance of HIV in "Mississippi Baby" poses questions for early treatment Aidsmap
Can U=U be used to reshape HIV programmes globally? - Aidsmap

German man remains free of HIV nearly 10 years after stem cell transplant - Aidsmap

German man remains free of HIV nearly 10 years after stem cell transplant Aidsmap
Long-acting injectable treatment maintains viral suppression - Aidsmap

Long-acting injectable treatment maintains viral suppression Aidsmap
Could antibodies be used for children with HIV instead of pills? - Aidsmap

Could antibodies be used for children with HIV instead of pills? Aidsmap
WHO HIVResNet HIV drug resistance laboratory operational framework - World Health Organization (WHO)

WHO HIVResNet HIV drug resistance laboratory operational framework World Health Organization (WHO)
At-home support after HIV diagnosis in Uganda helps people get on ART and stick with it - Aidsmap

At-home support after HIV diagnosis in Uganda helps people get on ART and stick with it Aidsmap
Fostemsavir salvage therapy continues to look good at 96 weeks - Aidsmap

Fostemsavir salvage therapy continues to look good at 96 weeks Aidsmap
Yes, the same life expectancy as HIV-negative people, but far fewer years in good health - Aidsmap

Yes, the same life expectancy as HIV-negative people, but far fewer years in good health Aidsmap
Six-country study shows dolutegravir-based treatment is highly effective in children and adolesce...

Six-country study shows dolutegravir-based treatment is highly effective in children and adolescents Aidsmap
The cornerstone of HIV treatment may be losing some of its power: will dolutegravir resistance be...

Experts shed light on coronavirus response and its implications for people with HIV - Aidsmap

Experts shed light on coronavirus response and its implications for people with HIV Aidsmap
Broadly neutralising antibodies may be partners for long-acting antiretrovirals - Aidsmap

Broadly neutralising antibodies may be partners for long-acting antiretrovirals Aidsmap
Oral lenacapavir can bridge gaps if injections must be missed - Aidsmap

Oral lenacapavir can bridge gaps if injections must be missed Aidsmap
Have HIV-associated neurological disorders declined in people with HIV due to recent antiretrovir...

Reduced-drug treatment becoming common in Paris - Aidsmap

The amber light: the World Health Organization’s position when an HIV viral load is “suppressed b...

Two PEP doses spaced a week apart protect monkeys from injected HIV; one dose might work in human...

Two PEP doses spaced a week apart protect monkeys from injected HIV; one dose might work in humans Aidsmap
Scientists use gene-edited stem cells to treat HIV — with mixed success - Nature

Scientists use gene-edited stem cells to treat HIV — with mixed success Nature
Biktarvy combination pill may be most effective option for people with HIV and hepatitis B - Aidsmap

Biktarvy combination pill may be most effective option for people with HIV and hepatitis B Aidsmap
Intermittent dosing on HIV dual therapy leads to higher rate of treatment failure - Aidsmap

Intermittent dosing on HIV dual therapy leads to higher rate of treatment failure Aidsmap
PD-1 inhibitor budigalimab may delay viral rebound - Aidsmap

Point-of-care viral load testing improves treatment outcomes and retention in care - Aidsmap

Point-of-care viral load testing improves treatment outcomes and retention in care Aidsmap
Novel, twice-a-year injected drug suppresses multidrug-resistant HIV in most patients on failing ...

Islatravir plus doravirine maintains viral suppression for a year - Aidsmap

Islatravir plus doravirine maintains viral suppression for a year Aidsmap
Home tests aren’t an accurate way for people on HIV treatment to check they still have HIV - Aidsmap

Home tests aren’t an accurate way for people on HIV treatment to check they still have HIV Aidsmap
The length of time Americans with HIV remain infectious is falling, but slowly - Aidsmap

The length of time Americans with HIV remain infectious is falling, but slowly Aidsmap
Sixfold increased risk of infant HIV infection and high rates of low birth weight among women wit...

HIV treatment in the womb helped five South African baby boys to stay undetectable off therapy - ...

HIV treatment in the womb helped five South African baby boys to stay undetectable off therapy Aidsmap
Earlier treatment and higher CD4 counts linked to smaller HIV reservoir - Aidsmap

Earlier treatment and higher CD4 counts linked to smaller HIV reservoir Aidsmap
Four days on, three days off HIV treatment as effective as continuous therapy, French study finds...

Four days on, three days off HIV treatment as effective as continuous therapy, French study finds Aidsmap
Adherence counselling reverses viral rebound on dolutegravir in 95% of cases - Aidsmap

Adherence counselling reverses viral rebound on dolutegravir in 95% of cases Aidsmap
Immune modulator clears pre-cancerous anal lesions - Aidsmap

Woman with HIV with low CD4 count remained positive on SARS-CoV-2 tests for over 5 months - Aidsmap

Woman with HIV with low CD4 count remained positive on SARS-CoV-2 tests for over 5 months Aidsmap
Black MSM are 60% less likely to have suppressed HIV than white men in Atlanta - Aidsmap

Black MSM are 60% less likely to have suppressed HIV than white men in Atlanta Aidsmap
Ibalizumab, active against highly resistant HIV, now approved in US - Aidsmap

Ibalizumab, active against highly resistant HIV, now approved in US Aidsmap
Weight gain on HIV treatment: drug combinations, not single drugs, need to be focus of quest for ...

Point-of-care viral load tests at delivery improve early preventive treatment for children at ris...

HIV incidence fell by three-quarters in Australian gay men, with strong association with treatmen...

Point-of-care viral load tests did not improve viral suppression in Kenyan children - Aidsmap

Point-of-care viral load tests did not improve viral suppression in Kenyan children Aidsmap
People with HIV express high satisfaction with monthly injectable regimen - Aidsmap

People with HIV express high satisfaction with monthly injectable regimen Aidsmap
More options for second-line treatment in children shown to be safe and effective - Aidsmap

More options for second-line treatment in children shown to be safe and effective Aidsmap
Who is at risk of injectable treatment failure? - Aidsmap

Switching to Biktarvy maintains viral suppression in people aged 65 or over - Aidsmap

Switching to Biktarvy maintains viral suppression in people aged 65 or over Aidsmap
Hepatitis C drops among HIV-positive London gay men after direct-acting antiviral scale-up - Aidsmap

Hepatitis C drops among HIV-positive London gay men after direct-acting antiviral scale-up Aidsmap
Lenacapavir plus broadly neutralising antibodies may offer twice-yearly treatment option - Aidsmap

Lenacapavir plus broadly neutralising antibodies may offer twice-yearly treatment option Aidsmap
Antiretroviral drug levels in hair strongly predict viral suppression - Aidsmap

Antiretroviral drug levels in hair strongly predict viral suppression Aidsmap
Long-acting injectables might be administered every two months - Aidsmap

Long-acting injectables might be administered every two months Aidsmap
African studies show that lowering viral load in the community reduces HIV incidence, but is not ...

Experimental antibody plus TLR7 agonist maintains viral suppression in monkeys - Aidsmap

Experimental antibody plus TLR7 agonist maintains viral suppression in monkeys Aidsmap
Progress on 90-90-90 HIV targets shows stark gap between eastern and western Europe - Aidsmap

Progress on 90-90-90 HIV targets shows stark gap between eastern and western Europe Aidsmap
Poor adherence associated with disruptive life events in young people living with HIV - Aidsmap

Poor adherence associated with disruptive life events in young people living with HIV Aidsmap
Dolutegravir-based HIV treatment is the safest and most effective choice for pregnant women - Aid...

Dolutegravir-based HIV treatment is the safest and most effective choice for pregnant women Aidsmap
Every-other-month injectable cabotegravir and rilpivirine suppresses viral load for two years - A...

Every-other-month injectable cabotegravir and rilpivirine suppresses viral load for two years Aidsmap
Dolutegravir-based second-line ART achieves excellent virological outcomes even in the presence o...

Bictegravir safe and effective in pregnancy - Aidsmap

Doravirine/islatravir just as effective as Biktarvy in previously untreated people - Aidsmap

Doravirine/islatravir just as effective as Biktarvy in previously untreated people Aidsmap
Recycling tenofovir better than switch to second-line zidovudine - Aidsmap

Recycling tenofovir better than switch to second-line zidovudine Aidsmap
Long-acting injectable treatment highly effective in European cohort studies - Aidsmap

Long-acting injectable treatment highly effective in European cohort studies Aidsmap
COVID-19 pandemic has speeded up the implementation of multi-month dispensing - Aidsmap

COVID-19 pandemic has speeded up the implementation of multi-month dispensing Aidsmap
Tenofovir (TDF) does not increase risk of kidney disease in people at low risk - Aidsmap

Tenofovir (TDF) does not increase risk of kidney disease in people at low risk Aidsmap
Options for two-drug simplification expand - Aidsmap

Co-administration of dolutegravir-based treatment and short course of rifapentine/isoniazid (3HP)...

Adolescent-centred interventions lead to a 30-percentage-point increase in viral suppression in N...

Fact check: List of US patents is not evidence that viruses are manmade - Reuters

Fact check: List of US patents is not evidence that viruses are manmade Reuters
Hepatitis C virtually eliminated in people with HIV in the Netherlands - Aidsmap

Hepatitis C virtually eliminated in people with HIV in the Netherlands Aidsmap
Viral suppression in Uganda improved by more viral load tests, done faster - Aidsmap

Viral suppression in Uganda improved by more viral load tests, done faster Aidsmap
HIV感染知りつつ300人以上と関係、米ミズーリ州の男を訴追 - Reuters

HIV感染知りつつ300人以上と関係、米ミズーリ州の男を訴追 Reuters